Anales de la RANM

58 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PROPAGACIÓN DE Aβ EN MODELOS MURINOS DE LA EA Andreo-Lopez J, et al. An RANM. 2023;140(01):49 - 58 20. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016; 8(6): 595-608. 21. Calderón-Garcidueñas AL, Duyckaerts C. Al- zheimer disease. Handb Clin Neurol. 2018; 145: 325-337. 22. Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci. 2020; 23(10): 1183-1193. 23. Gibbons GS, Lee VMY, Trojanowski JQ. Mecha- nisms of cell-to-cell transmission of patholo- gical tau: a review. JAMA Neurol. 2019; 76(1): 101-108. 24. Holtzman DM, Carrillo MC, Hendrix JA et al. Tau: From research to clinical development. Al- zheimers Dement. 2016; 12(10): 1033-1039. 25. Hardy J, Higgins G. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992; 256(5054): 184-185. 26. Moreno-González I, Soto C. Misfolded protein aggregates: Mechanisms, structures and poten- tial for disease transmission. Semin Cell Dev Biol. 2011; 22(5): 482-487. 27. Morales R, Durán-Aniotz C, Castilla J et al. De novo induction of amyloid-β deposition in vivo. Mol Psychiatry. 2012; 17(12): 1347-1353. 28. Morales R, Durán-Aniotz C, Bravo-Alegría J et al. Infusion of blood from mice displaying ce- rebral amyloidosis accelerates amyloid patho- logy in animal models of Alzheimer’s disease. Acta Neuropathol Commun. 2020; 8(213): 1-16. 29. Meyer-Luehmann M, Coomaraswamy J, Bol- mont T et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006; 313(5794): 1781-1784. 30. Eisele YS, Obermüller U, Heilbronner G et al. Peripherally applied Abeta-containing inocula- tes induce cerebral beta-amyloidosis. Science. 2010; 330(6006): 980-982. 31. Hamaguchi T, Eisele YS, Varvel NH et al. The presence of Aβ seeds, and not age per se, is cri- tical to the initiation of Aβ deposition in the brain. Acta Neuropathol. 2012; 123(1): 31-37. 32. Friesen M, Meyer-Luehmann M. Aβ Seeding as a tool to study cerebral amyloidosis and as- sociated pathology. Front Mol Neurosci. 2019; 12(233): 1-9. 33. Condello C, Lemmin T, Stöhr J et al. Structu- ral heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer’s disease. Proc Natl Acad Sci USA. 2018; 115(4): E782– E791. 34. Makowski L. The structural basis of amyloid strains in Alzheimer’s disease. ACS Biomater Sci Eng. 2020; 6(5): 2498-2505. 35. Tian Y, Meng L, Zhang Z. What is strain in neurodegenerative diseases? Cell Mol Life Sci. 2020; 77(4): 665-676. 36. Morales R, Moreno-González I, Soto C. Cross- seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog. 2013; 9(9): 1-4. 37. Stöhr J, Watts JC, Mensinger ZL et al. Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions. Proc Natl Acad Sci USA. 2012; 109(27): 11025-11030. 38. Bu XL, Xiang Y, Jin WS et al. Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies. Mol Psychiatry. 2018; 23(9): 1948- 1956. 39. Ridley RM, Baker HF, Windle CP, Cummings RM. Very long term studies of the seeding of β-amyloidosis in primates. J Neural Transm. 2006; 113(9): 1243-1251. 40. Ritchie DL, Adlard P, Peden AH et al. Amyloid-β accumulation in the CNS in human growth hor- mone recipients in the UK. Acta Neuropathol. 2017; 134(2): 221-240. 41. Baglietto-Vargas D, Forner S, Cai L et al. Ge- neration of a humanized Aβ expressing mouse demonstrating aspects of Alzheimer’s disease- like pathology. Nat Commun. 2021; 12(1): 1-16. 42. Trujillo-Estrada L, Sánchez-Mejías E, Sánchez- Varo R et al. Animal and cellular models of Alzheimer’s disease: Progress, promise, and future approaches. Neuroscientist. 2022; 28(6): 572-593. Si desea citar nuestro artículo: Andreo-Lopez J, Bettinetti-Luque M, Campos-Moreno C, Gutierrez A, Baglietto-Vargas D. Agregación y propagación de Aβ en mo- delos transgénicos de la enfermedad de Alzheimer. An RANM. 2023;140(01): 49– 58. DOI: 10.32440/ar.2023.140.01 . rev05